Newsletter Volume 39, Number 5, 2024
Introduction
This summer’s heat wave was memorable, but it has gradually begun to look more like autumn. This summer has been filled with excitement over the hot competition among athletes at the Olympic and Paralympic Games, news of Dodger Otani’s brilliant performance, and many other topics that make us dream. Speaking of dreams, I recently attended a historic conference for the first time in many years, and was impressed by the importance of “talking about dreams” in the discussions during the conference. Certainly, when people talk about their dreams, it is human nature to want to see them come true, to share the same problems, to think of solutions, to expand the discussion, and to encounter ideas that one might not have expected. When I joined a pharmaceutical company, my dream was to become a researcher who could identify the metabolic position of a compound by looking at its structure, since my job was to analyze the structure of metabolites. I remember the excitement and motivation for structural analysis when unpredictable metabolic reactions occurred, and it was both nostalgic and sobering. Now that the Corona Disaster is over and we are back to face-to-face discussions, it would be interesting to discuss with each other about the dreams we would like to realize. In pharmacokinetic research, which is at the forefront of the diversification of drug discovery modalities, it is necessary to incorporate technologies from various fields and utilize them in a timely manner. There may be few opportunities to talk about dreams in the field of research, but what are your dreams? We are busy in our daily lives, but it is good to take a break once in a while and think about them. (K.I.)
Topics
Pharmacokinetic Society of Japan Newsletter: Regulatory Science Information
The Newsletter Committee reports on regulatory science information related to the field of pharmacokinetics, including the latest trends in guidelines and regulatory harmonization activities at ICH. ( For more information, please visit the NL website.)
NEW POWER for pharmacokinetic research
Development of new intestinal and hepatic cell models using iPS cells and genome editing technology
Laboratory of Molecular Pharmacokinetics, Ritsumeikan University
Ryosuke Negoro
My name is Ryosuke Negoro, Faculty of Pharmaceutical Sciences, Ritsumeikan University. I would like to thank the editorial board members and everyone involved for the opportunity to contribute to the newsletter of the Japanese Society of Pharmacokinetics and Pharmacodynamics, “New Power for Pharmacokinetics Research. I entered the Faculty of Pharmaceutical Sciences of Setsunan University in 2009 and belonged to the Laboratory of Pharmacotherapeutics, which was led by Professor Sadaaki Maeda. After graduating from Setsunan University, I entered the Graduate School of Pharmaceutical Sciences at Osaka University, where I studied in the Department of Molecular Biology led by Professor Hiroyuki Mizuguchi and received my degree in March 2019. In April of the same year, I joined the Laboratory of Molecular Pharmacokinetics in the Faculty of Pharmaceutical Sciences, Ritsumeikan University, led by Professor Takuya Fujita, as an Assistant Professor. In this paper, I would like to introduce the results of my research to date and my future plans. … ( To be continued at NL website / Members only )
Introduction of Technology and Research Materials (Company Advertisement)
Visualization and Quantification of Drugs/Metabolites by Highly Sensitive and Fast Targeted DESI Imaging with a Tandem Quadrupole Mass Spectrometer
Waters Corporation
LC-MS/MS is commonly used to measure drug concentrations in tissues in pharmacokinetic studies, but information on compound distribution is lost due to homogenization of the tissue during sample preparation. On the other hand, desorption electrospray ionization (DESI) mass spectrometry imaging (MSI) technology enables visualization and quantification of compound distribution information without radiolabeling. In this study, we present results of distribution studies of unchanged drug, major metabolites, and endogenous metabolites in major organs of the narcolepsy drug Pitrisant after administration of the active and toxic dose volumes using DESI MSI. … ( visit the NL website for more information )